Clinical trials: Melanoma, Stage I
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma
- Trial name
- NCT02498665
- Testing
- DSP-7888 Dosing Emulsion
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8
- Trial name
- NCT07040280
- Testing
- Biopsy Procedure, Biospecimen Collection, Sulforaphane
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Malignant Melanoma
Vaccine Treatment for Advanced Malignant Melanoma
This 2-phase study will determine the safety of treating patients with malignant melanoma with the genetically engineered HyperAcute-Melanoma vaccine.
- Trial name
- NCT00300612
- Testing
- HyperAcute-Melanoma Vaccine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- NewLink Genetics Corporation
Solid Tumor, Melanoma
OH2 Injection in Solid Tumors
This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).
- Trial name
- NCT04386967
- Testing
- OH2 injection, Keytruda
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Melanoma
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
Patients with advanced stage melanoma who underwent vaccination with the Melan-A/MART-1 peptide and who display detectable levels of Melan-A specific CD8+ T cells in peripheral blood are eligible for this trial.
- Trial name
- NCT00160992
- Testing
- Melan-A analog peptide
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- University of Lausanne Hospitals
Choroidal Melanoma
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal…
- Trial name
- NCT00765921
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Melanoma
A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma
This is a single center, open phase I dose escalation study. This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV…
- Trial name
- NCT01672450
- Testing
- Intratumoral Ipilimumab and Interleukin-2
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Primary Liver Cancer, SCLC
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.
- Conditions
- Primary Liver Cancer, SCLC, Lymphoma, Melanoma
- Trial name
- NCT01829971
- Testing
- MRX34
- Where
- 10 sites in United States, South Korea
- Volunteers
- 155 people
- Sponsor
- Mirna Therapeutics, Inc.
Sarcoma, Osteosarcoma
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas.
- Conditions
- Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
- Trial name
- NCT02107963
- Testing
- Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Cutaneous Melanoma, Stage II, Cutaneous Melanoma
Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma
The primary goal of this clinical trial is to is to compare the rate of positive peripheral margins in wide local excision (WLE) performed to allow for comprehensive peripheral and deep margin assessment (CPDMA) assessment versus…
- Conditions
- Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
- Trial name
- NCT07869381
- Testing
- Wide Local Excision
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- University of Nebraska
Solid Tumors
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this trial was to explore the clinical utility of two investigational agents in patients with advanced cancer. This was a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT03301896
- Testing
- LHC165, PDR001
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Leptomeningeal Metastasis, Solid Tumor, Adult
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Adults with leptomeningeal metastasis from solid tumors will be treated with 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3.
- Trial name
- NCT04315246
- Testing
- radiolabeled DPTA-omburtamab
- Where
- 8 sites in United States, United Kingdom
- Sponsor
- Y-mAbs Therapeutics
Bladder Carcinoma, Breast Cancer
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Background: Autologous T cells engineered to express a T cell receptor (TCR) targeting NY-ESO-1 will be infused back to patients with NY-ESO-1- expressing malignancies.
- Conditions
- Bladder Carcinoma, Breast Cancer, Esophagus Carcinoma, Lung Cancer
- Trial name
- NCT02457650
- Testing
- Cyclophosphamide, Fludarabine, Anti-NY ESO-1 TCR-transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT01989585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 49 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center